Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labcorp HoldingsLTS:0JSY +1.86%80 EV-to-EBIT is 21.46 as of Jul. 18, 2026, which is 33% above its 10-year median of 16.14. GuruFocus rates LTS:0JSY with a GF Score™ of 80/100 and a GF Value™ of $270.03 (Fairly Valued). The stock has 6 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Labcorp Holdings ranks better than 51.92% on this metric.
The historical rank and industry rank for Labcorp Holdings's EV-to-EBIT or its related term are showing as below:
LTS:0JSY'
s EV-to-EBIT Range Over the Past 10 Years
Min: 6.78 Med: 16.14 Max: 32.44
Current: 21.46
During the past 13 years, the highest EV-to-EBIT of Labcorp Holdings was 32.44. The lowest was 6.78. And the median was 16.14.
LTS:0JSY's EV-to-EBIT is ranked better than 51.92% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 23.035
vs LTS:0JSY: 21.46
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Labcorp Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $28,044 Mil.
Labcorp Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,375 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labcorp Holdings EV-to-EBIT Related Terms
Labcorp Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Labcorp Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Labcorp Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labcorp Holdings EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Labcorp Holdings's EV-to-EBIT falls into.
Labcorp Holdings's current Enterprise Value is $29,512 Mil.
Labcorp Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,375 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labcorp Holdings (LTS:0JSY) has a EV-to-EBIT of 21.46 as of Jul. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Labcorp Holdings and its competitors. This is 33% above median its historical median of 16.14. Over the past decade, Labcorp Holdings' EV-to-EBIT has ranged from 6.78 to 32.44. According to the industry distribution chart, Labcorp Holdings ranks #50 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 48.1%.
Is Labcorp Holdings' EV-to-EBIT too high?
Labcorp Holdings' current EV-to-EBIT of 21.46 is 33% above median its 10-year median of 16.14. Over the past 10 years, this metric has ranged from a low of 6.78 to a high of 32.44. The Medical Diagnostics & Research industry median EV-to-EBIT is 23.04. Labcorp Holdings' value of 21.46 is 6.8% below this industry median. Based on the distribution chart, Labcorp Holdings ranks #50 out of 104 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Labcorp Holdings has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Labcorp Holdings' EV-to-EBIT compare to DGX and GH?
According to the Medical Diagnostics & Research industry distribution chart, Labcorp Holdings ranks #50 out of 104 companies for EV-to-EBIT. This puts Labcorp Holdings in the upper half of its industry. The industry median EV-to-EBIT is 23.04. Labcorp Holdings' value of 21.46 is 6.8% below this benchmark. Historically, Labcorp Holdings' own EV-to-EBIT has ranged from 6.78 to 32.44 over the past decade. While the company's 10-year median is 16.14 vs. the industry median of 23.04, Labcorp Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.04, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labcorp Holdings's current EV-to-EBIT of 21.46 is 6.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Labcorp Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labcorp Holdings's current EV-to-EBIT is 21.46, which is 33% above median its own 10-year median of 16.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labcorp Holdings stock overvalued right now?
Based on GuruFocus' analysis, Labcorp Holdings (LTS:0JSY) is currently considered Fairly Valued. The stock's GF Value™ is $270.03, compared to a current price of $282.00 — trading 4.4% above its estimated fair value. The current EV-to-EBIT is 21.46, which is 33% above median its 10-year median of 16.14 and 6.8% below the Medical Diagnostics & Research industry median of 23.04. Labcorp Holdings' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Labcorp Holdings (LTS:0JSY), the current EV-to-EBIT is 21.46 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labcorp Holdings (LTS:0JSY) Overvalued in 2026?
Based on GuruFocus' analysis, Labcorp Holdings stock appears to be overvalued.
The current stock price of $282.00 is trading 4.4% above its estimated GF Value™ of $270.03.
GuruFocus considers Labcorp Holdings to be Fairly Valued.
Key valuation signals for LTS:0JSY:
EV-to-EBIT: 21.46 (33% above median its 10-year median of 16.14)
GF Value™: $270.03 vs. price of $282.00 (4.4% above fair value)
Industry Position: 6.8% below the Medical Diagnostics & Research median (#50 of 104)
No single metric tells the full story. See the LTS:0JSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
80GF Score
Get the complete analysis for LTS:0JSY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JSY has been successfully added to your 
